Share ownership Gilead Sciences, Inc.

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 15/05/2026 BST			5-day change	1st Jan Change
129.58 ^USD	-1.88%		-1.33%	+5.57%

05-15	Mubadala Investment Co PJSC raises share stake in AbbVie, Match Group, cuts in CVS Health	RE
05-15	Wall Street Wanted More

Share class: Gilead Sciences, Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	1,241,569,874	1,239,981,677 ( 99.87 %)	0	99.87 %

Major shareholders: Gilead Sciences, Inc.

Name	Equities	%	Valuation
Vanguard Capital Management LLC 7.519 %	93,327,127	7.519 %	12 211 M $
BlackRock Advisors LLC 6.894 %	85,570,223	6.894 %	11 196 M $
Vanguard Capital Management LLC 6.498 %	80,654,776	6.498 %	10 553 M $
Fidelity Management & Research Co. LLC 5.787 %	71,823,555	5.787 %	9 397 M $
STATE STREET CORPORATION 4.823 %	59,858,585	4.823 %	7 832 M $
Capital Research & Management Co. (World Investors) 3.326 %	41,283,933	3.326 %	5 402 M $
Vanguard Portfolio Management LLC 2.83 %	35,129,465	2.83 %	4 596 M $
JPMorgan Investment Management, Inc. 2.739 %	33,992,410	2.739 %	4 448 M $
Ishares (DE) InvAG mit Teilgesellschaftsvermogen 2.478 %	30,761,386	2.478 %	4 025 M $
Geode Capital Management LLC 2.395 %	29,726,052	2.395 %	3 889 M $
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
BRAM - Bradesco Asset Management SA DTVM 0.000078 %	1,929	0.000078 %	124 295 $

Breakdown by shareholder type

Institutional	80.99%
Other	8.87%
State Street Corp.	4.82%
Schweizerische Nationalbank	0.29%
Sumitomo Mitsui Trust Group, Inc.	0.24%
Governments	0.2%
Swedbank AB	0.19%
SEI Investments Co.	0.13%
Manulife Financial Corp.	0.1%
Individuals	0.09%
Danske Bank A/S	0.07%
The Bank of Nova Scotia	0.06%
Fifth Third Bancorp	0.05%
Münchener Rückversicherungs-Gesellschaft AG	0.04%
Migdal Insurance & Financial Holdings Ltd.	0.04%
Banco Bilbao Vizcaya Argentaria SA	0.03%
Zurich Insurance Group AG	0.03%
ING Groep NV	0.02%
ABN AMRO Bank NV	0.02%
The Allstate Corp.	0.01%
BNP Paribas Fortis SA/NV	0.01%
Banque Cantonale Vaudoise	0.01%
Hennessy Advisors, Inc.	0.01%
First Horizon Corp. (Tennessee)	0.01%
Unknown	3.67%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	71.63%
United Kingdom	8.21%
Canada	3.06%
Germany	3.05%
Norway	1.9%
France	1.38%
Sweden	1.03%
Switzerland	0.97%
Australia	0.94%
Japan	0.79%
Denmark	0.71%
Netherlands	0.48%
Hong Kong	0.34%
South Korea	0.33%
Belgium	0.23%
Luxembourg	0.22%
Ireland	0.16%
Italy	0.14%
China	0.12%
Individuals	0.09%
Austria	0.09%
Finland	0.09%
Spain	0.09%
New Zealand	0.06%
Israel	0.04%
Singapore	0.04%
Czech Republic	0.03%
Malaysia	0.03%
Taiwan	0.02%
South Africa	0.02%
United Arab Emirates	0.01%
India	0.01%
Russia	0.01%

Based on 1000 largest holdings

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).

Employees

17,000

Sector

Pharmaceuticals

Calendar

06-15 - Ex-dividend date - 0.82 USD

More about the company